Pharmacological therapies for NASH treatment are widely investigated such as insulin sensitizers (metformin and pioglitazone), antioxidants (vitamin E and pentoxifylline), cholesterol-lowering drugs (statins and aramchol), farnesoid X receptor (FXR) agonists (obeticholic acid [OCA] and tropifexor), peroxisome proliferator-activated receptors (PPARs; elafibranor and saroglitazar), thyroid hormone receptor (THR; resmetirom), and glucagon-like peptide (GLP)-1 agonist (liraglutide and semaglutide). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.